Marksans Pharma (MARKSANS) Aperçu de l'action
Marksans Pharma Limited, avec ses filiales, se consacre à la recherche, à la fabrication, au marketing et à la vente de formulations pharmaceutiques aux États-Unis, en Amérique du Nord, en Europe, au Royaume-Uni, en Australie, en Nouvelle-Zélande et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 2/6 |
| Performances passées | 5/6 |
| Santé financière | 5/6 |
| Dividendes | 3/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour MARKSANS à partir de nos contrôles de risques.
MARKSANS Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Marksans Pharma Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹316.45 |
| Plus haut sur 52 semaines | ₹349.95 |
| Plus bas sur 52 semaines | ₹155.00 |
| Bêta | 1.15 |
| Variation sur 1 mois | -4.53% |
| Variation sur 3 mois | 21.04% |
| Variation sur 1 an | 76.55% |
| Variation sur 3 ans | 206.79% |
| Variation sur 5 ans | 357.63% |
| Évolution depuis l'introduction en bourse | 1,063.63% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Sep 03
MARKSANS: Dividend Payout And Acquisition Plans Will Shape Measured Future Share Rerating
Analysts have lifted their fair value estimate for Marksans Pharma from about ₹266 to around ₹324, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples. What’s in the News for Marksans Pharma Shareholders of Marksans Pharma approved a final dividend of ₹0.90 per equity share with a face value of ₹1 for the financial year ended 31 March 2026 at the annual general meeting held on 27 August 2026.Article d’analyse • Aug 15
Marksans Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
The investors in Marksans Pharma Limited 's ( NSE:MARKSANS ) will be rubbing their hands together with glee today...
Mise à jour du récit • Aug 14
MARKSANS: Higher Margin Outlook And Dividend Plans Will Support Upside Potential
The analyst price target for Marksans Pharma has been revised from ₹298 to ₹385, with analysts pointing to updated assumptions for discount rates, revenue growth, profit margins, and future P/E as the key drivers of this change. What’s in the News for Marksans Pharma A board meeting is scheduled on 12 August 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.Recent updates
Mise à jour du récit • Sep 03
MARKSANS: Dividend Payout And Acquisition Plans Will Shape Measured Future Share Rerating
Analysts have lifted their fair value estimate for Marksans Pharma from about ₹266 to around ₹324, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples. What’s in the News for Marksans Pharma Shareholders of Marksans Pharma approved a final dividend of ₹0.90 per equity share with a face value of ₹1 for the financial year ended 31 March 2026 at the annual general meeting held on 27 August 2026.Article d’analyse • Aug 15
Marksans Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
The investors in Marksans Pharma Limited 's ( NSE:MARKSANS ) will be rubbing their hands together with glee today...Mise à jour du récit • Aug 14
MARKSANS: Higher Margin Outlook And Dividend Plans Will Support Upside Potential
The analyst price target for Marksans Pharma has been revised from ₹298 to ₹385, with analysts pointing to updated assumptions for discount rates, revenue growth, profit margins, and future P/E as the key drivers of this change. What’s in the News for Marksans Pharma A board meeting is scheduled on 12 August 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.Mise à jour du récit • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.Nouveau récit • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Nouveau récit • Jun 01
Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?Article d’analyse • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Article d’analyse • May 28
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Article d’analyse • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Article d’analyse • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Article d’analyse • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Mise à jour du récit • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Article d’analyse • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Mise à jour du récit • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Article d’analyse • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Article d’analyse • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Article d’analyse • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...Article d’analyse • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...Article d’analyse • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Article d’analyse • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Article d’analyse • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Article d’analyse • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Article d’analyse • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
Nouveau récit • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Article d’analyse • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Article d’analyse • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Article d’analyse • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Article d’analyse • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Article d’analyse • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Article d’analyse • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Article d’analyse • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rendement pour les actionnaires
| MARKSANS | IN Pharmaceuticals | IN Marché | |
|---|---|---|---|
| 7D | -4.1% | -2.4% | -2.9% |
| 1Y | 76.6% | 13.2% | -3.9% |
Rendement vs Industrie: MARKSANS a dépassé le secteur Indian Pharmaceuticals qui a rapporté 13.2 % au cours de l'année écoulée.
Rendement vs marché: MARKSANS a dépassé le marché Indian qui a rapporté -3.9 % au cours de l'année écoulée.
Volatilité des prix
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Cours de l'action stable: MARKSANS n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de MARKSANS ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1992 | 1,685 | Mark Saldanha | marksanspharma.com |
Marksans Pharma Limited, avec ses filiales, se consacre à la recherche, à la fabrication, au marketing et à la vente de formulations pharmaceutiques aux États-Unis, en Amérique du Nord, en Europe, au Royaume-Uni, en Australie, en Nouvelle-Zélande et dans le monde entier. L'entreprise propose des produits dans les domaines thérapeutiques suivants : traitement de la douleur, respiratoire supérieur, cardiovasculaire, système nerveux central, antidiabétique, gastro-intestinal, analgésique, respiratoire supérieur, soins des oreilles, soins de la peau, anticancéreux, anti-ulcéreux, anti-allergique, antiviral, diététique, cardiaque, dermatologique, antihistaminique, antifongique, antiviral, laxatif, et rhume et toux. Elle produit également une gamme de formes solides de dosage par voie orale, notamment des comprimés et des capsules de gélatine dure, des gels mous, des huiles essentielles, des pommades, des crèmes et des liquides, ainsi que des médicaments délivrés sur ordonnance.
Marksans Pharma Limited Résumé des fondamentaux
| MARKSANS statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹143.40b |
| Bénéfices(TTM) | ₹5.17b |
| Recettes(TTM) | ₹31.72b |
27.8x
Ratio P/E4.5x
Ratio P/SLe site MARKSANS est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MARKSANS compte de résultat (TTM) | |
|---|---|
| Recettes | ₹31.72b |
| Coût des recettes | ₹14.20b |
| Marge brute | ₹17.52b |
| Autres dépenses | ₹12.35b |
| Les revenus | ₹5.17b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 11.40 |
| Marge brute | 55.25% |
| Marge bénéficiaire nette | 16.29% |
| Ratio dettes/capitaux propres | 11.2% |
Quelles ont été les performances à long terme de MARKSANS?
Voir les performances historiques et les comparaisonsDividendes
0.3%
Rendement actuel des dividendes10%
Ratio de distributionLe site MARKSANS verse-t-il des dividendes fiables ?
Voir MARKSANS l'historique des dividendes et les indices de référence| Marksans Pharma dates des dividendes | |
|---|---|
| Date ex-dividende | Aug 20 2026 |
| Date de paiement du dividende | Sep 26 2026 |
| Jours jusqu'au dividende Ex | 28 days |
| Jours jusqu'à la date de paiement du dividende | 9 days |
Le site MARKSANS verse-t-il des dividendes fiables ?
Voir MARKSANS l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/16 19:59 |
| Cours de l'action en fin de journée | 2026/09/16 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Marksans Pharma Limited est couverte par 4 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |